Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04189952
Title Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Miami
Indications

lymphoma

Therapies

Acalabrutinib + Carboplatin + Etoposide + Ifosfamide + Rituximab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.